In Xianxi Section of 321 National Highway in Shishan, Nanhai, several buildings with more than ten stories are particularly conspicuous in the middle of a low factory building. Careful attention can be found that enterprises have begun to enter the building. This is an important place for the project incubation and industrialization of Guangdong Biomedical Industry Base in Foshan High-tech Zone.

       Foshan Anpuze Biomedical Co., Ltd. (hereinafter referred to as "Anpuze") is one of the leading enterprises stationed in the industrialization, mainly engaged in the research and development of biological macromolecular drugs and pilot-scale. At present, its first project variety (National Class II New Drug, Monoclonal Antibody) has been declared for clinical trials two years ago. It has passed the development site verification and the re-examination of the Chinese People's Procuratorate smoothly. After the submission of supplementary information in April this year, it is expected to pass the clinical approval in the near future.

       For more information, please refer to the source document: http://epaper.southcn.com/nfdaily/html/2016-05/27/content_7550641.htm